



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No. 056324-0129

Re patent application of

R. Tyler WHITE et al.

Serial No. 10/076,604

Filed: February 19, 2002

For: PROTEASE INHIBITOR PEPTIDES

Group Art Unit: 1652

Examiner: Unassigned

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Prior to Examination on the merits, please amend the application as follows:

IN THE CLAIMS:

Please cancel claims 1-79 without prejudice or disclaimer.

Please add the following new claims.

80. (New) A method of treating a clinical condition associated with increased activity of one or more serine proteases, comprising administering to a patient suffering from said clinical condition an effective amount of a pharmaceutical composition comprising a polypeptide selected from at least one of the following sequences:

(DD103) EVVREVCSEQAETGPCRAMIFRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:130)

(DD104) EVVREVCSEQAETGPCRAMIYRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:131)

(DD105) EVVREVCSEQAETGPCRAMIWRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:132)

(TW6182) EVVREVCSEQAETGPCRAMIHRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:134)

(TW6194) EVVREVCSEQAETGPCRAMIERWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:135)

(DD185) EVVREVCSEQAETGPCRAAIFRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:171)

(TW6165) EVVREVCSEQAETGPCRAAIWRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:172)

(TW6166) EVVREVCSEQAETGPCRAAIYRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:173)

(BG028) EVVREVCSEQAETGPCRALIYRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:174)

(TW6175)EVVREVCSEQAETGPCRALIFRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:177)
(TW6201)EVVREVCSEQAETGPCRAGIYRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:178)
(TW6202)EVVREVCSEQAETGPCRAGIWRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:179)
(DD114)EVVREVCSEQAETGPCRAAISRWYFDVTEGKCAPFFYGGCRGNRNNFDTEEYCMVCGSAI (SEQ ID NO:183)
(TW6183)EVVREVCSEQAETGPCRAMHFRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:185)
(TW6184)EVVREVCSEQAETGPCRAMHYRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:186)
(TW6185)EVVREVCSEQAETGPCRAMHWRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:187)
(BG003)EVVREVCSEQAETGPCRAMLHRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:188)
(TW6187)EVVREVCSEQAETGPCRAMIFRWYFDVTEGKCAPFFYGGCYGNRNNFDTEEYCMVCGSAI (SEQ ID NO:190)
(TW6188)EVVREVCSEQAETGPCRAMIYRWYFDVTEGKCAPFFYGGCYGNRNNFDTEEYCMVCGSAI (SEQ ID NO:191)
(TW6189)EVVREVCSEQAETGPCRAMIWRWYFDVTEGKCAPFFYGGCYGNRNNFDTEEYCMVCGSAI (SEQ ID NO:192)
(DD115)EVVREVCSEQAETGPCRGYITRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:194)
(TW6176)EVVREVCSEQAETGPCRAAHFRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:196)
(TW6177)EVVREVCSEQAETGPCRALHFRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:197)
(BG006)EVVREVCSEQAETGPCRAALFRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:198)
(DD130)EVVREVCSEQAETGPCRALFTRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:199)
(BG014)EVVREVCSEQAETGPCRALIWHWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:204)
(DD122)EVVREVCSEQAETGPCRALIFAWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:205)
(BG015)EVVREVCSEQAETGPCRALIYHWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:206)
(BG020)EVVREVCSEQAETGPCRAAIHKWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:207)
(BG022)EVVREVCSEQAETGPCRAAIYHWYFDVTEGKCAPFFYGGCGGNRNNFDTEEHCMVCGSAI (SEQ ID NO:208)
(BG024)EVVREVCSEQAETGPCRALIYKWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:210)
(DD116)EVVREVCSEQAETGPCRAAIFRWYFDVTEGKCAPFFYGGCRGNRNNFDTEEYCMVCGSAI (SEQ ID NO:212)
(TW6191)EVVREVCSEQAETGPCRAAIFRWYFDVTEGKCAPFFYGGCYGNRNNFDTEEYCMVCGSAI (SEQ ID NO:213)
(BG029)EVVREVCSEQAEGPCRALIYHWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:215)
(BG030)EVVREVCSEQAESGPCRALIYHWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:216)
(BG033)EVVREVCSEQAEGPCRAAIYHWYFDVTEGKCAPFFYGGCGGNRNNFDTEEHCMVCGSAI (SEQ ID NO:217)
(BG034)EVVREVCSEQAESGPCRAAIYHWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:218)
(BG040)EVVREVCSEQAEGPCRALIYHWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:219)
(BG025)EVVREVCSEQAETGPCRGLIYHWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:223)
(BG026)EVVREVCSEQAETGPCRGAIYHWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:224)

81. (New) A method for inhibiting activity of at least one serine protease in a mammal comprising administering a therapeutically effective dose of a pharmaceutical composition, together with a pharmaceutically acceptable sterile vehicle, wherein said composition comprises a polypeptide selected from at least one of the following sequences:

(DD103) EVVREVCSEQAETGPCRAMIFRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:130)
(DD104) EVVREVCSEQAETGPCRAMIYRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:131)
(DD105) EVVREVCSEQAETGPCRAMIWRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:132)
(TW6182) EVVREVCSEQAETGPCRAMIHRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:134)
(TW6194) EVVREVCSEQAETGPCRAMIERWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:135)
(DD185) EVVREVCSEQAETGPCRAAIFRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:171)
(TW6165) EVVREVCSEQAETGPCRAAIWRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:172)
(TW6166) EVVREVCSEQAETGPCRAAIYRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:173)
(BG028) EVVREVCSEQAETGPCRALIYRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:174)
(TW6175) EVVREVCSEQAETGPCRALIFRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:177)
(TW6201) EVVREVCSEQAETGPCRAGIYRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:178)
(TW6202) EVVREVCSEQAETGPCRAGIWRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:179)
(DD114) EVVREVCSEQAETGPCRAAISRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:183)
(TW6183) EVVREVCSEQAETGPCRAMHFRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:185)
(TW6184) EVVREVCSEQAETGPCRAMHYRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:186)
(TW6185) EVVREVCSEQAETGPCRAMHWRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:187)
(BG003) EVVREVCSEQAETGPCRAMLHRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:188)
(TW6187) EVVREVCSEQAETGPCRAMIFRWYFDVTEGKCAPFFYGGCYGNRNNFDTEEYCMVCGSAI (SEQ ID NO:190)
(TW6188) EVVREVCSEQAETGPCRAMIYRWYFDVTEGKCAPFFYGGCYGNRNNFDTEEYCMVCGSAI (SEQ ID NO:191)
(TW6189) EVVREVCSEQAETGPCRAMIWRWYFDVTEGKCAPFFYGGCYGNRNNFDTEEYCMVCGSAI (SEQ ID NO:192)
(DD115) EVVREVCSEQAETGPCRGYITRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:194)
(TW6176) EVVREVCSEQAETGPCRAAHFRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:196)
(TW6177) EVVREVCSEQAETGPCRALHFRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:197)
(BG006) EVVREVCSEQAETGPCRAALFRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:198)
(DD130) EVVREVCSEQAETGPCRALFTRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:199)
(BG014) EVVREVCSEQAETGPCRALIWHWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:204)
(DD122) EVVREVCSEQAETGPCRALIFAWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:205)
(BG015) EVVREVCSEQAETGPCRALIYHWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:206)
(BG020) EVVREVCSEQAETGPCRAAIHKWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:207)
(BG022) EVVREVCSEQAETGPCRAAIYHWYFDVTEGKCAPFFYGGCGGNRNNFDTEEHCMVCGSAI (SEQ ID NO:208)

(BG024)EVVREVCSEQAETGPCRALIYKWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:210)
(DD116)EVVREVCSEQAETGPCRAAIFRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:212)
(TW6191)EVVREVCSEQAETGPCRAAIFRWYFDVTEGKCAPFFYGGCYGNRNNFDTEEYCMVCGSAI (SEQ ID NO:213)
(BG029)EVVREVCSEQAEVGPCRALIYHWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:215)
(BG030)EVVREVCSEQAESGPCRALIYHWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:216)
(BG033)EVVREVCSEQAEVGPCRAAIYHWYFDVTEGKCAPFFYGGCGGNRNNFDTEEHCMAVCGSAI (SEQ ID NO:217)
(BG034)EVVREVCSEQAESGPCRAAIYHWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:218)
(BG040)EVVREVCSEQAIEGPCRALIYHWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:219)
(BG025)EVVREVCSEQAETGPCRGLIYHWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:223)
(BG026)EVVREVCSEQAETGPCRGAIYHWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:224)

REMARKS

Claims 1-79 have been cancelled and claims 80 and 81 have been added. The new claims are identical to previous claims 81 and 105 of the parent application with serial number 09/201,715. Claims 81 and 105 were indicated as allowable in the Office Action mailed March 23, 2000 (Paper No. 10). As these claims were indicated as allowable, applicants submit that this application is in condition for allowance.

Should the Examiner have any questions concerning this application, please contact applicant's undersigned representative at the number below.

Respectfully submitted,

September 11, 2002

Date

FOLEY & LARDNER
Suite 500
3000 K Street, N.W.
Washington, DC 20007-5109
Telephone: (202) 672-5300
Facsimile: (202) 672-5399



Matthew E. Mulkeen

Reg. No. 44,250